Clinical Trials Browser

Phase 2 × Endometrial Adenocarcinoma × trastuzumab biosimilar HLX02 × Clear all

NCT00006089 2019-07-31

Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Phase 2 Completed

Endometrial Adenocarcinoma